Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05634876 · ClinicalTrials.gov registry record · Phase 1
UB-312 in Patients With Synucleinopathies
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05634876 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants.
The verdict
NCT05634876, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1b study to determine the safety, tolerability, and immunogenicity of UB-312 in participants with multiple system atrophy (MSA), and in participants with Parkinson's disease (PD). UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine and may provide an active immunotherapy option for treating synucleinopathies including the most prevalent form, PD; and the most rapidly progressive form, MSA.
Interventions
- BIOLOGICAL UB-312 Injection
- BIOLOGICAL Placebo Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2025-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05634876
The ClinicalTrials.gov registry entry for NCT05634876 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which UB-312 Injection is the first listed.
NCT05634876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05634876 about?
NCT05634876 is a clinical study titled "UB-312 in Patients With Synucleinopathies". This is a Phase 1b study to determine the safety, tolerability, and immunogenicity of UB-312 in participants with multiple system atrophy (MSA), and in participants with Parkinson's disease (PD). UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine and may provide an active immunotherapy opti...
What is the current status of trial NCT05634876?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-05-31. Estimated completion is 2025-02-11.
What interventions are being tested in trial NCT05634876?
The interventions under investigation include: UB-312 Injection (BIOLOGICAL), Placebo Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT05634876?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.